These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30260324)

  • 1. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
    Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
    J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
    Oon ML; Hoppe MM; Fan S; Phyu T; Phuong HM; Tan SY; Hue SS; Wang S; Poon LM; Chan HLE; Lee J; Chee YL; Chng WJ; de Mel S; Liu X; Jeyasekharan AD; Ng SB
    Leuk Lymphoma; 2019 Dec; 60(13):3214-3224. PubMed ID: 31259656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
    Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
    J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of aurora A and polo-like kinases in high-risk lymphomas.
    Murga-Zamalloa C; Inamdar KV; Wilcox RA
    Blood Adv; 2019 Jun; 3(11):1778-1787. PubMed ID: 31186254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLK1: a promising and previously unexplored target in double-hit lymphoma.
    Hassan QN; Alinari L; Byrd JC
    J Clin Invest; 2018 Dec; 128(12):5206-5208. PubMed ID: 30395539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
    Hugle M; Belz K; Fulda S
    Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
    Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
    Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
    Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
    Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
    Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
    Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer.
    Li J; Ohmura S; Marchetto A; Orth MF; Imle R; Dallmayer M; Musa J; Knott MML; Hölting TLB; Stein S; Funk CM; Sastre A; Alonso J; Bestvater F; Kasan M; Romero-Pérez L; Hartmann W; Ranft A; Banito A; Dirksen U; Kirchner T; Cidre-Aranaz F; Grünewald TGP
    Nat Commun; 2021 Sep; 12(1):5356. PubMed ID: 34531368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.
    Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X
    Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
    Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
    Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.